Dataset from A Multicenter, Phase III, Open-Label, Randomized Study in Previously Untreated Patients With Advanced Indolent Non-Hodgkin's Lymphoma Evaluating the Benefit of GA101 (RO5072759) Plus Chemotherapy Compared With Rituximab Plus Chemotherapy Followed by GA101 or Rituximab Maintenance Therapy in Responders

This open-label, randomized study will assess the efficacy and safety of obinutuzumab
(RO5072759) in combination with chemotherapy compared to rituximab (MabThera/Rituxan) with
chemotherapy followed by obinutuzumab or rituximab maintenance in participants with untreated
advanced indolent non-Hodgkin's lymphoma. After the end of the induction period, participants
achieving response (Complete response [CR] or partial response [PR]) will undergo a
maintenance period continuing on the randomized antibody treatment alone every 2 months until
disease progression for a total of 2 years. Anticipated time on study treatment is up to
approximately 2.5 years. After maintenance or observation, participants will be followed for
5 years until progression. After progression, participants will be followed for new
anti-lymphoma therapy and overall survival until the end of the study.